¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06
±³À°ÀÏÀÚ : 2022-11-06
±³À°Àå¼Ò : ÄÚ¿¢½º ³²ÂÊ4Ãþ ÄÁÆÛ·±½º·ë  
±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ) ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÁöÀºÁ¤
¿¬¶ôó : 02-512-5915  
À̸ÞÀÏ : gyncancer@gyncancer.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í Àü¹®ÀÇ 5¸¸¿ø, Àü°øÀÇ3¸¸¿ø, ¿¬±¸¿ø/°£È£»ç2¸¸¿ø, ÁÂÀå/¿¬ÀÚ/Åä·ÐÀÚ/¸¸65¼¼ÀÌ»ó ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-06 401È£ 09:00~09:10 ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best Reviewer ½Ã»ó½Ä  () 
±âŸ 11-06 401È£ 09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±âŸ 11-06 401È£ 09:15~09:20 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±³À°½Ã°£ 11-06 401È£ 09:20~09:35 Ovarian cancer  ³²¼ÒÇö(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:35~09:40 Designated discussion  ÀÌÀºÁö(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 09:40~09:55 Cervical cancer and uterine cancer  ³ëÁØÈ£(¼º±Õ°üÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:55~10:00 Designated discussion  Àü¼·(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:00~10:15 Risk classification of endometrial cancer  ¹Ú¼öÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:15~10:30 BRCA and HRD in high-grade ovarian cancer  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:30~10:45 PD-L1, TMB, MMR status, and beyond for immunotherapy  ÃÖÀ±Áø(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 401È£ 10:45~11:00 Designated discussion  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
È޽Ġ11-06 401È£ 11:00~11:20 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 11:20~11:35 Will the importance of complete cytoreduction continue or shrink?  ±èÅÂÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 11:35~11:50 HIPEC or not, that is the question  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-06 401È£ 11:50~12:05 Are you ready for relapse after PARP inhibitors?  ¹ÚÁ¤¿­(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 12:05~12:20 Designated discussion  Á¤´ëÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:20~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:35~12:50 Long-term results of PARPi as maintenance in front-line  Antonio González Martín(Clínica Universidad de Navarra) 
½Ä»ç 11-06 401È£ 12:50~13:40 Lunch  () 
±³À°½Ã°£ 11-06 401È£ 13:40~13:55 Less radical surgery in early-stage cervical cancer  ¹èÀ縸(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 13:55~14:10 Quality indicators of the radical surgery  °øÅ¿í(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:10~14:25 CCRT: current standard & future perspective  ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) 
Åä·Ð 11-06 401È£ 14:25~14:40 Designated discussion  ³ëÁÖ¿ø(Â÷ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:40~14:55 Fertility-preservation in gynecologic cancers  ÀÌ»óÈÆ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:55~15:10 How to optimize elderly patients for cancer treatments?  ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 15:10~15:25 Management of immunotherapy and targeted therapies-induced toxicities  ÀåűÔ(°è¸íÀÇ´ë) 
Åä·Ð 11-06 401È£ 15:25~15:40 Designated discussion  ¹Ú¼ºÈ£(ÇѸ²ÀÇ´ë) 
È޽Ġ11-06 401È£ 15:40~16:00 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 16:00~16:15 Uterine sarcoma  ¼Ò°æ¾Æ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:15~16:30 Ovarian clear cell cancer  ¼­µ¿¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:30~16:45 Ovarian low grade serous cancer  È«´ë±â(°æºÏÀÇ´ë) 
Åä·Ð 11-06 401È£ 16:45~17:00 Designated discussion  ±Çº´¼ö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 13:40~13:55 Assessment of quality of cancer patients  Á¶ÁÖÈñ(¼º±Õ°ü´ë À¶ÇÕÀÇ°úÇпø) 
±³À°½Ã°£ 11-06 403È£ 13:55~14:10 Tailored surgery for cervical cancer  ±¸À¯Áø(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:10~14:25 Guidelines and issues for ovarian cancer treatment  ±è»óÀÏ(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 403È£ 14:25~14:35 Discussion  () 
±³À°½Ã°£ 11-06 403È£ 14:35~14:50 ERAS & perioperative management  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:50~15:05 Issue of nursing problem during the acute survival period  ±èÁÖÇö(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 11-06 403È£ 15:05~15:20 Clinical trial and research ethics related to gynecologic oncology  ±è¼ö(¿¬¼¼´ë °£È£´ëÇÐ) 
Åä·Ð 11-06 403È£ 15:20~15:30 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºÐ´ç¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ)¾È°úÁúȯÀÇ ÃÖ½ÅÁö°ß(½Ç¸í±Ùó¿¡ ´Ù´Ù¸¥ ³ì³»Àå) : 2022-11-08
´ÙÀ½±Û 2022³â Á¦21Â÷ ¾Æ½Ã¾ÆÇÙÀÇÇÐÇù·Â±â±¸ Çмú´ëȸ ¹× Á¦61Â÷ ´ëÇÑÇÙÀÇÇÐȸ Ãß°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-11-05
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 45 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 35 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 37 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 46 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 38 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 30 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 12 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 12 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 29 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 14 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 12 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 33 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 23 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 27 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 22 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷